Antibody suppliers

We at Novus Biologicals have a large antibody database devoted to signalling pathways. These underpin every area of molecular biological research, including cancer. Among our cell signalling antibodies is one targeted to DLL4 (Delta-like protein 4). DLL4 is a homologue of the Drosophila delta gene, known to encode DSL-domain ligands on the Notch signaling pathway.

Most commercially available antibodies produced with traditional immunization technology, using peptides or other immunogens isolated and purified from cell lysates.

Typically, mice are immunized with the antigen in groups, varying the mouse strain and antigen dosage. Pre-immune and immune sera are evaluated and mice showing the best immune response are selected for somatic cell fusion. This is the fusion of antibody-producing lymphocytes with proprietary myeloma cells from a non-antibody producing source, creating a hybridoma.

Novus Biologicals recently added novel GAT (Genomic Antibody Technology) reagents to our antibody catalog, following the formation of a partnership with SDIX, creators of the technique. SDIX's GAT antibodies represent a totally new way to think about protein immunogens.

Novus Biologicals offers an extensive antibody databasecovering all areas of biological research. Recently, we dramatically increased the scope of our antibody catalog by adding over 800 antibodies created  using Genomic Antibody Technology (GAT), through a new partnership with SDIX (Strategic Diagnostics, Inc.). As we begin creating novel GAT reagents of our own, this database will expand still further – as there are many GAT antibodiesstill to be created.

Ago2, also called eIF2C2, antibody is one of 37 reagents targeted to the Argonaute protein family that we at Novus Biologicals have in our antibody catalogue. Argonaute proteins are encoded by genes which play an important role in regulating the control of gene expression by miRNA (microRNA). Recently, a new antibody study showed that the role of Ago2 may be to help generate production of miRNA, rather than simply moderate its function.

Death-receptor apoptosis, or cell death, is essential for cellular growth regulation; its disruption is expressed in a variety of cancers. We at Novus Biologicals are one of the leading antibody suppliersfor apoptosis and cancer research groups, and therefore have a large antibody database targeting death receptor proteins.

Recently, we at Novus Biologicals became partners with Strategic Diagnostics Inc (SDIX), one of the largest antibodyproducers in the US. The objective was to extend our antibody database by over 800 of SDIX's polyclonal cancer antibodies, created by their unique Genomic Antibody Technology (GAT) system, as well as creating novel GAT immunoglobulins against targets specific to our own antibody catalog. However, what exactly is GAT, and why is it so superior?

Novus has made quite an appearance at many tradeshows this summer in Europe. At each show, we offered a drawing to win an iPad and presented our Antibody Princesses. The iPad winner at the 7th Federation of European Neuroscience Societies Forum in Amsterdam was Alejandro Garcia (pictured below) and the winner at the 21st Meeting of the European Association for Cancer Research in Oslo was Fabio Cattaneo.

We at Novus Biologicals offer many antibodies relevant to cancer research. Among the areas covered by our antibody catalog are the nuclear matrix proteins, which include the heterogeneous nuclear ribonucleoproteins (hnRNPs). hnRNP antibodies were recently used in a new study in gastric cancer treatment.

We at Novus Biologicals offer a full antibody database targeted to transcription factor research. Recently, CEBP antibodieswere used in a research study exploring the evolution of gene regulation in various vertebrates. The results revealed surprising discrepancies between genomes, and the conservation of transcription factor function over large evolutionary distances.